KalVista Pharmaceuticals Inc (4XC1 F) stock market data APIs
€16.3393
0(0%)
as of April 2, 2026
Try our APIs with
free plan!
KalVista Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.
Prev. Close
16.3393
Open
16.3393
High
16.3393
Low
16.3393
52 wk Range
9-17.1
Market Cap
875 M
Shares Outstanding
51 222 K
Revenue
73 617 K
Beta
-0.399
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get KalVista Pharmaceuticals Inc data using free add-ons & libraries
Get KalVista Pharmaceuticals Inc Fundamental Data
KalVista Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 73 617 K
- EBITDA: -164 816 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-25
- EPS/Forecast: -0.53
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
KalVista Pharmaceuticals Inc News
New
Insider Sell: Chief Scientific Officer Edward Feener Sells 22,679 Shares of KalVista ...
KalVista Pharmaceuticals Inc (NASDAQ:KALV), a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant un...
Insider Sell: Chief Scientific Officer Edward Feener Sells 17,321 Shares of KalVista ...
Edward Feener, Chief Scientific Officer of KalVista Pharmaceuticals Inc (NASDAQ:KALV), executed a sale of 17,321 shares in the company on January 9, 2024, according to a recent SEC Filing. KalVista Ph...
Insider Sell: CEO Thomas Crockett Sells 30,000 Shares of KalVista Pharmaceuticals Inc (KALV)
On December 27, 2023, Thomas Crockett, CEO of KalVista Pharmaceuticals Inc (KALV), sold 30,000 shares of the company's stock, according to a recent SEC Filing. This transaction is part of a series of ...
16 Most Promising Long-Term Stocks According to Analysts
In this piece, we will take a look at the 16 most promising long-term stocks according to analysts. If you want to skip our overview of long term investing, then you can take a look at 5 Most Promisin...
Get KalVista Pharmaceuticals Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
